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Opioids
Abstract

Clinical Question Are different opioid agonist treatments (eg, methadone vs buprenorphine) associated with
differences in efficacy for treating prescription opioid dependence, and is long-term maintenance of opioid
agonist treatment associated with differences in efficacy compared with opioid taper or psychological
treatments alone? Bottom Line For patients who are dependent on prescription opioids, long-term
maintenance of opioid agonists is associated with less prescription opioid use and better adherence to
medication and psychological therapies for opioid dependence compared with opioid taper or psychological
treatments alone. Methadone maintenance was not associated with differences in therapeutic efficacy
compared with buprenorphine maintenance treatment. Evidence quality was low to moderate.
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JAMA Clinical Evidence Synopsis

Opioid Agonist Treatment for Patients With Dependence
on Prescription Opioids
Suzanne Nielsen, BPharm, PhD; Briony Larance, PhD; Nicholas Lintzeris, MBBS, PhD

CLINICAL QUESTION Are different opioid agonist treatments (eg, methadone vs
buprenorphine) associated with differences in efficacy for treating prescription opioid
dependence, and is long-term maintenance of opioid agonist treatment associated with
differences in efficacy compared with opioid taper or psychological treatments alone?
BOTTOM LINE For patients who are dependent on prescription opioids, long-term
maintenance of opioid agonists is associated with less prescription opioid use and better
adherence to medication and psychological therapies for opioid dependence compared with
opioid taper or psychological treatments alone. Methadone maintenance was not associated
with differences in therapeutic efficacy compared with buprenorphine maintenance
treatment. Evidence quality was low to moderate.

Introduction

Methadone vs Buprenorphine

(assessed during final 30 days of the intervention, 1.51 days [SD,
4.97 days] for methadone vs 2.92 days [SD, 6.38 days] for
buprenorphine; mean difference, −1.41 [95% CI, −3.37 to 0.55];
P = .16), opioid use as measured by opioid-positive urine drug
screening (27 of 79 participants [34.2%] for methadone vs 51 of 117
participants [43.6%] for buprenorphine; risk ratio [RR], 0.81 [95%
CI, 0.56 to 1.18]; P = .28), and self-reported opioid use (11 of 66 participants [16.7%] for methadone vs 34 of 89 participants [38.2%]
for buprenorphine; RR, 0.37 [95% CI, 0.08 to 1.63]; P = .19). No
between-group difference was found in treatment adherence for
methadone (Table).

Three studies compared methadone with buprenorphine (Table).
No difference was found in the mean number of days of opioid use

Buprenorphine Maintenance vs Opioid Taper

The United States is experiencing an opioid overdose epidemic, with
recentincreasesinprescriptionopioid–relatedmortality.1,2 Opioidagonist treatment is recommended for treating prescription opioid dependence by the US Centers for Disease Control and Prevention.3 This
Clinical Evidence Synopsis summarizes findings from a Cochrane review that aimed to summarize current evidence for the treatment of
prescription opioid dependence using opioid agonist treatments.4

Summary of Findings

Evidence Profile
No. of studies: 6 randomized clinical trials
Study years: Conducted: 2002-2014; published: 2003-2015
Last search date: May 13, 2015
Number of participants: 607
Men: 77% Women: 33%
Race/ethnicity: 86% white (reported in 3 studies)
Age, mean (range): 32 years (17-60 years; reported in 3 studies)
Setting: Outpatient; 1 study recruited from emergency
departments
Countries: United States and Iran
Comparisons: (1) Different opioid agonist maintenance treatments
(methadone vs buprenorphine) and (2) maintenance treatment
(buprenorphine) vs opioid taper and vs psychological
treatment alone.
Primary Outcomes: Illicit opioid use and treatment adherence
(attending counseling visits, taking prescribed medication
per protocol, or both).
Secondary Outcomes: Pain, injecting behaviors, quality of life,
physical and psychological health.
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Three studies compared buprenorphine maintenance with opioid
taper or psychological treatment only. No between-group difference was found for mean days of opioid use during past 7 days or
30 days (standardized mean difference, −0.31 [95% CI, −0.66 to
0.04]; P = .08). Buprenorphine maintenance treatment was associated with reduced opioid use as determined by urine opioidpositive drug screening (39 of 97 participants [40.2%] vs 67 of 109
participants [61.5%] with opioid taper; RR, 0.63 [95% CI, 0.43 to
0.91]; P = .02) and reduced opioid use by self-report (37 of 100 participants [37.0%] vs 62 of 104 participants [59.6%] with opioid
taper; RR, 0.54 [95% CI, 0.31 to 0.93]; P = .003). Buprenorphine
maintenance therapy was associated with greater treatment
adherence (83 of 110 participants [75.5%] vs 36 of 137 participants
[26.3%] with opioid taper; RR, 0.33 [95% CI, 0.23 to 0.47];
P < .001).

Discussion
No difference was found in treatment outcomes between methadone and buprenorphine maintenance therapy in prescription
opioid dependence treatment. Maintenance treatment was associated with better substance use and treatment adherence outcomes compared with shorter-term treatments. Updated searches
(conducted in August 2016) identified no additional eligible trials.
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Table. Opioid Agonist Treatments for Prescription Opioid Dependence
Range, wk
Treatment
No. of
Primary Outcomes
Studies Duration
Studies That Compared Methadone With Buprenorphine
Illicit opioid use during final 30 d
of the intervention
Opioid-positive urine drug screening
at treatment completion
Self-reported substance use at end
of treatment
Adherenceg

Total
Follow-up

1

24

32

2

24 to 26

26 to 32

Methadone
Total
No.a
No.
1.51
(4.97)c
27

53
79

Buprenorphine
Total
No.a
No.
Risk Ratio (95% CI)
2.92
76
(6.38)c
51
117

P
Value

Quality of
the Evidence
(GRADE)b

−1.41 (−3.37 to 0.55)d

.16e

Moderate

0.81 (0.56 to 1.18)

.28f

Moderate

f

2

24 to 26

26 to 32

11

66

34

89

0.37 (0.08 to 1.63)

.19

Moderate

3

24 to 26

24 to 32

121

162

125

198

0.69 (0.39 to 1.22)h

.20f

Low

Studies That Compared Buprenorphine Maintenance With Opioid Taper or Psychological Treatment Only
Buprenorphine
69

NAj

64

−0.31 (−0.66 to 0.04)d

.08e

Low

Illicit opioid use

2

4 to 14

4 to 14

NA

Opioid-positive urine drug screening
at treatment completion
Self-reported opioid use at end
of treatment
Adherenceg

3

4 to 14

4 to 52

39

97

67

109

0.63 (0.43 to 0.91)

.02f

Low

3

4 to 14

4 to 52

37

100

62

104

0.54 (0.31 to 0.93)

.003e

Low

3

4 to 14

4 to 52

83

110

36

137

0.33 (0.23 to 0.47)h

Abbreviations: GRADE, Grading of Recommendations, Assessment,
Development and Evaluations; NA, not available.

d

Indicates mean difference (95% CI).

e

Calculated using inverse variance.

<.001f

Moderate

a

Unless otherwise indicated.

f

Calculated using the Mantel-Haenszel test.

b

Moderate defined as moderately confident in the effect estimate (ie, true
estimate is likely to be close to the estimate of the effect, but there is a
possibility that it is substantially different); and low, confidence in the effect
estimate is limited (ie, the true effect may be substantially different from the
estimate of the effect).

g

Attended counseling visits, took prescribed medication, or both per protocol.

h

The analyses represents the risk of someone being nonadherent.

i

Or psychological treatment only.

j

Had different denominators (ie, past 7 days or 30 days) in different studies;
therefore, the results were calculated using the standard mean difference.

c

Indicates mean (SD).

Limitations

Most studies were conducted in the United States. No studies used
a double-blind method, and all studies had relatively small sample
sizes (53-204 participants). Due to the overall low to moderate quality of the evidence and sample sizes, it is possible further research
may change these conclusions.
Comparison of Findings With Current Practice Guidelines

The US Center for Substance Abuse Treatment guidelines5 and
A Guideline for the Clinical Management of Opioid Addiction6 suggest that long-term treatment is preferable to withdrawal treatment alone, consistent with the findings of this review. The American Society of Addiction Medicine guidelines7 concluded that
evidence supports methadone and buprenorphine maintenance,
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Opioid Taperi

j

consistent with the results of this review, and that treatment setting (supervised dosing in a drug treatment clinic vs treatment provided in a physician’s office) is important when taking into account
patient preference and safety considerations.
Areas in Need of Future Study

Further research should include examining the treatment of concurrent chronic pain and opioid dependence and comparing
outcomes for psychological treatment and taper. Inclusion of validated pain measures in future studies will facilitate a better understanding of pain as it relates to treatment of opioid addiction. See
JAMA opioid microsite (http://sites.jamanetwork.com/opioids/) for
further clinical information such as differences between methadone
and buprenorphine induction.
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